

PTO/SB/08A (08-03) (modified)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
ark Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
Substitute for to	m 1449/P10			Application Number	10/511,115	
TN	EODMAT	TION DISC	OCUDE	Filing Date	June 23, 2005	
_				First Named Inventor	Ola Karlsson	
STATEMENT BY APPLICANT				Art Unit	1713	
	(Use as many sheets as necessary)			Examiner Name	Ives J. Wu	
				Attorney Docket Number	1103326-0781	
Sheet	1	Of	3			

	_	U.S. 1	PATENT DOCUME	NTS	
Examiner	Cite	Document Number	Publication Date	Name of Patentee	Pages, Columns, Lines, Where
Initials	No.	Number-Kind Code <sup>2 (If traven)</sup>	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages/Figures Appear
J-W		3,775,537	11/27/1973	Lehmann et al.	·
d-W		4,784,858	11/15/1988	Ventouras	
11-00		5,085,866	02/04/1992	Cowsar et al.	
8-0		5,260,068	11/09/1993	Chen	
1.0		5,478,573	12/26/1995	Eichel et al.	
Jul		5,292,522	03/08/1994	Petereit et al.	
J.W	1 1	5,529,790	06/25/1996	Eichel et al.	
D-W		5,721,313	02/24/1998	Yeung et al	

		FOREIGN I	PATENT DOCUM						
Examiner Initials	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>3</sup> (if bnown)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T			
JW	<del> </del>	WO 99/30685	06/24/1999	Lee et al.	Of Resevant rigures repeat	$\vdash$			
	<del>                                     </del>	WO 99/42087	08/26/1999	Nagy et al.	+	╁╴			
1-W		WO 00/13686	03/16/2000	Wolff et al.	<del> </del>	╁			
Ja-W		WO 00/13686 WO 00/13687	03/16/2000	Wolff		╁╌			
dew.	<del> </del>	EP 0 403 959 A1	12/27/1990	Petereit et al.		╁			
1-W		EP 0 403 939 A1	04/08/1987	Ruffner		╁			
N/W	1-		07/15/1987	Morita et al.		╀			
J.W	-	EP 0 228 879 A2			+	<b>├</b>			
tra		CH 484 960 A	03/13/1970	Derra et al.		÷			
M.W	ل	GB 1,141,165	01/29/1969	Derra et al.	1	ᅩ			
Examiner	Cite		ITERATURE DO		item (book, magazine, journa).				
Initials	No.	serial, symposium, catalog, etc.), date, page	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
YM		YOSHINOBU FUKUMORI et al., "Coating Aqueous Coating with Ethyl Acrylate-Met Dissolution Properties of the Products"; C	ng of Pharmaceutical thyl Methacrylate-2-H	Powders by Fluidized I lydroxyethyl Methacryl	Bed Process. III. 1) ate Copolymer and the				
JW		Abstract of JP 01-113322 A, Tomoaki et a 1988.	al, issued January 31,	1970, publication of ap	olication February 5,	,			
7 m		HIDEKI ICHIKAWA et al., "Coating of F Microencapsulation Using Blend and Con Hydroxyethyl Methacrylate)"; Chem. Pha	posite Latices of Cop	oly (Ethyl Acrylate-Me	ocess. VI. 1) hthyl Methacrylate-2-				

EXAMINER: billst if reference considered, whether or not citation is in conformance with MPEP 609. Draw time through citation if not in conformance and on considered, bother copy of this form with next communication to applicam. Applicam's unique citation designation number (optionals). See Kinch Codes of USPTO Patent Documents and way to prove MPEP 90.104. Enter Officer that issued the documents, by the report of the region of the Empore unity present by the serial number of the patent documents. We designate that issued the documents and the difference of the extension of the patent documents. We designed that issued the document and the VIPO Standard \$7.1.15 (possible. "Applicam is to place a check must beer if English bengang Frantisation is standard. This collection of information is required by 17 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to the (end by the USPTO to process) an application. Confidentiality is presented by 31 USC. 122 and 31.88. L1. This collection is estimated to take? Journ to complete, including gardening, preparing, and adminising the completed application form to the USPTO. Time will very depending upon the individual case. Any comments on the smooth of time you require to complete this form and/or suggestions for reducing this borden, should be seen to the Chief habstension of Officer, U.S. Patent and Tradenark Office, P.O. Box 1450, Alexandria, VA 21313-1450.

PTO/SB/08A (08-03) (modified)
Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Puperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless a contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
Substitute for	10m 1449/F10			Application Number	10/511,115	
INFORMATION DISCLOSURE				Filing Date	June 23, 2005	
				First Named Inventor	Ola Karlsson	
S	STATEMENT BY APPLICANT (Use as many sheets as necessary)			Art Unit Examiner Name	1713 Ives J. Wu	
				Attorney Docket Number	1103326-0781	
Sheet	2	of	3			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т
7-0		HIDEKI ICHIKAWA et al., "Coating of Pharmaceutical Powders by Fluidized Bed Process. V. 1) Agglomeration and Efficiency in the Coating with Aqueous Latices of Copoly (Ethyl Acrylate-Methyl Methacrylate-2-Hydroxyethyl Methacrylate)"; Chem. Pharm. Bull., vol. 41, no. 6, 1132-1136, (1993).	
4.2		RAGNARSSON et al., "Development of a New Controlled Release Metoprolol Product"; Drug Development and Industrial Pharmacy, vol. 13, no. 9-11, 1495-1509, (1987).	
J.W		SANDBERG et al., "Design of a New Multiple-Unit Controlled-Release Formulation of Metoprolol – Metoprolol CR"; European Journal of Clinical Pharmacology, vol. 33, no. 33, 3-7, (1988).	
1. W		SANDBERG et al., "Pharmacokinetic and Pharmacodynamic Properties of a New Controlled –Release Formulation of Metoprolol: A Comparison with Conventional Tablets"; European Journal of Clinical Pharmacology, vol. 33, no. 33, 9-14, (1988).	
1.0		RAGNARSSON et al., "In Vitro Release Characteristics of a Membrane-Coated Pellet Formulation – Influence of Drug Solubility and Particle Size"; International Journal of Pharmaceutics, vol. 79, 223-232, (1992).	
J-W		SANDBERG et al., "Influence of Dissolution Rate on the Extent and Rate of Bioavailability of Metoprolol"; International Journal of Pharmaceutics, vol. 68, 167-177, (1991).	•
W-10		SANDBERG et al., "Steady-State Bioavailability and Day-to-Day Variability of Multiple-Unit (CR/ZOK) and a Single Unit (OROS) Delivery System of a Metoprolol After Once-Daily Dosing"; Pharmaceutical Research, vol. 10, no. 1, 28-34, (1993).	
1.w		SANDBERG et al., "Pharmacokinetics of Metoprolol Enantiomers after Administration of the Racemate and the S-Enantiomer as Oral Solutions and Extended Release Tablets"; Drug Invest, vol. 6, no. 6, 320-329, (1993).	
7-00		SANDBERG, "Extended-Release Metoprolol"; Thesis, Uppsala University, (1994).	
NW		PETEREIT et al., "Formulation and Process Considerations Affecting the Stability of Solid Dosage Forms Formulated with Methacrylate Copolymers"; European Journal of Pharmaceutics and Biopharmaceutics, vol. 47, 15-25, (1999).	
J-M		PETEREIT et al., "Glyceryl Monostearate as a Glidant in Aqueous Film-Coating Formulations"; European Journal of Pharmaceutics and Biopharmaceutics, vol. 41, no. 4, 219-228, (1995).	
4-W		AMIGHI et al., "Influence of Curing Conditions on the Drug Release Rate from Eudragit NE30D Film Coated Sustained-Release Theophylline Pellets"; S.T.P. Pharma Sciences, vol. 7, no. 2, 141-147, (1997).	
J.W		BODMEIER et al., Mechanical Properties of Dry and Wet Cellulosic and Acrylic Films Prepared from Aqueous Colloidal Polymer Dispersions Used in the Coating of Solid Dosage Forms"; Pharmaceutical Research, vol. 11, no. 6, 882-888, (1994).	
Jew		OZTURK et al., Mechanism of Release from Pellets Coated with an Ethylcellulose-Based Film"; Journal of Controlled Release, vol. 14, 203-213, (1990).	
1-0		GOODHART et al., "An Evaluation of Aqueous Film-Forming Dispersions for Controlled Release"; Pharmaceutical Technology, 64-71, April (1984).	
Examiner Sig	gnature	Date Considered 11-4-05	

EXAMINER: binid if reference considered. whether or not citation is in conformance with MPEP 609. Draw time through citation if our in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (options). See Kinds Codes of USFTO Patent Documents at whether any of MPEP 901.04. Enter Office that issued the document, by the two-least code (WIPO Standard ST.3). Yes represent a present of the patent options confidencement by the appropriate symbols as indicated on the channel under WIPO Standard ST.3). The information is required on the channel under WIPO Standard ST.3). The information is required to express the appropriate symbols as indicated on the channel under WIPO Standard ST.3. This collection is client on the appropriate symbols as indicated on the channel under WIPO Standard ST.3. This collection is client on the standard on the channel under WIPO Standard ST.3. This collection is centimed to take I hours to complete including gathering, preparing, and establishing the completed application form so the USFTO. Time will very depending upon the individual case. Any commons on the amount of time you require to complete this form and/or appraisant as the amount of the present and Trademark Office, I.S. Passet and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

DATE CONSIDERED FORM TO THIS ADDRESS. SEND TO: Commissioner for Passets, P.O. Box 1450, Alexandria, VA 22313-1450.

•

PTO/SB/08A (08-03) (modified)
Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless a contains a valid OMB control number.

Substitute for form 1449/PTO			*	Complete if Known		
Substitute to	1449/PIQ			Application Number	10/511,115	
1	INFORMAT	TON DIC	TOSIDE	Filing Date	June 23, 2005 Ola Karlsson	
				First Named Inventor		
,	STATEMEN	T BY AP	PLICANT	Art Unit	1713	
	(Use as many sheets as necessary)			Examiner Name	Ives J. Wu	
				Attorney Docket Number	1103326-0781	
Sheet	3	of	3		1.	

Examin <del>er</del> Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
Jas		BODMEIER et al., "Plasticizer Uptake by Aqueous Colloidal Polymer Dispersions Used for the Coating of Solid Dosage Forms"; International Journal of Pharmaceutics, vol. 152, 17-26, (1997).					
J-W		G. COLE, Table of Contents: "Pharmaceutical Coating Technology"; published by Taylor and Francis Ltd., (1995).					
7 W		GUTIERREZ ROCCA, Ph.D., "Stability and Physical-Mechanical Properties of Acrylic Resin Copolymers"; Thesis, The University of Texas at Austin, (1993).					
1,0		HJARTSTAM, "Ethyl Cellulose Membranes Used in Modified Release Formulations"; Thesis, Chalmers University of Technology, Goteborg, (1998).					
1.0		LINDSTEDT et al., "Osmotic Pumping as a release Mechanism for membrane-Coated Drug Formulations"; International Journal of Pharmaceutics, vol. 56, 261-268, (1989).					
1.W		K. KOLTER et al., "KOLLICOAT®SR 30 D – Coatings on Different Drugs"; Proceed. Int'l. Symp. Control. Rel. Bioact. Mater, vol. 27, 425-426, (2000).					
7.0		BODMEIER et al., "The Effect of Curing on Drug Release and Morphological Properties of Ethylcellulose Pseudolatex-Coated Beads"; Drug Development and Industrial Pharmacy, vol. 20, no. 9, 1517-1533, (1994).					
1-m		WILKINSON et al., "The Cleaning of Polymer Colloids"; Advances in Colloid and Interface Science; vol. 81, 77-165, (1999).	<u> </u>				
<del></del>	ļ						
<del>-</del>	<del> </del>		<del> </del>				
	-						
	<del> </del>						
	gnature	Date Considered 11-7-05	_				

EXAMINER: binisi if reference considered, whether or not ciusion is in conformance with MPEP 609. Draw line through ciusion if not in conformance and not considered backdes copy of this form with next communication to applicantly impract aution designation number (options). See Kinds Codes of USPTO Parent Documents at www.nprog.gov or MPEP 901.04. Enter Office that issued the document, by the revolution code (WIPFO Standard ST.3). For Impraces patient document, he indication of the year of the reign of the Emperor must preced the sorial number of the patient document. Nith of forement by the appropriate symbols as indicated on the document ander WIPO Standard ST.16 (possible. "Applicant is to place a check mark here if English tale garage (Tamahatico is masched. This collection of information by TCPR 1.17 and 1.93. The information is required by 10 CPR 1.17 and 1.93. The information is required by 10 CPR 1.19 and 1.93. The information is required to obtain or reasin a benefit by the public (in and by the USPTO to process) an application. Confidentially it governed by 31 U.S.C. 112 and 37 CPR 1.14. This collection of a community are a community gratering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any community on the amount of time you require to complete this form and/or augmentions for reducing this burden, should be sent to the Chief Information Officer, U.S. Putton and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORM TO THIS ADDRESS. SEND TO: Commissioner for Parents, P.O. Box 1450, Alexandria, VA 22311-1450.